Krystal Biotech (KRYS) Competitors

Summit Therapeutics (NASDAQ:SMMT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Which has stronger earnings & valuation, SMMT or KRYS?

Krystal Biotech has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	$700K	29,401.82	-$614.93M	-$0.31	-90.00
Krystal Biotech	$290.52M	16.53	$10.93M	$2.99	55.57

Do analysts rate SMMT or KRYS?

Summit Therapeutics presently has a consensus price target of $37.40, suggesting a potential upside of 34.05%. Krystal Biotech has a consensus price target of $222.71, suggesting a potential upside of 34.04%. Given Summit Therapeutics' higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is SMMT or KRYS more profitable?

Krystal Biotech has a net margin of 30.69% compared to Summit Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-85.42%	-52.66%
Krystal Biotech	30.69%	11.41%	10.40%

Do institutionals and insiders believe in SMMT or KRYS?

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, SMMT or KRYS?

Summit Therapeutics has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Does the media refer more to SMMT or KRYS?

In the previous week, Krystal Biotech had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 29 mentions for Krystal Biotech and 24 mentions for Summit Therapeutics. Krystal Biotech's average media sentiment score of 0.93 beat Summit Therapeutics' score of 0.86 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer SMMT or KRYS?

Summit Therapeutics received 16 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.73% of users gave Krystal Biotech an outperform vote while only 58.65% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Summit Therapeutics	Outperform Votes 312 58.65%	Underperform Votes 220 41.35%
Krystal Biotech	Outperform Votes 296 67.73%	Underperform Votes 141 32.27%

Summary

Krystal Biotech beats Summit Therapeutics on 13 of the 18 factors compared between the two stocks.